| 生物活性 |
Alisol A 24-acetate (Alisol A monoacetate) is an orally active protostane-type tetracyclic triterpenoid derivative that upregulates adiponectin, AMPKα, CPT1, and ACOX1; downregulates the expression of SREBP-1c, ACC, FAS, Bcl-2, Bcl-xl, PPAR-γ, perilipin A, and NFATc1; inhibits the activities of PI3K/Akt/mTOR and HMGR; activates the PKA and ERK signaling pathways; and regulates apoptosis, autophagy, hepatic lipid accumulation, inflammatory responses, neuroprotection, MRSA membrane integrity, and osteoclast differentiation, thereby being applicable to research on non-alcoholic fatty liver disease, nephrotoxicity, obesity, global cerebral ischemia-reperfusion injury, bacterial infection, and osteoporosis. |
体外研究 (In Vitro) |
Alisol A 24-acetate (2.5-100 μM; 24 h) 可呈剂量依赖性降低 HepG2 细胞活力,孵育 24 h 后,浓度高于 10 μM 时可观察到显著的细胞毒性。 Alisol A 24-acetate (10 μM; 24 h) 可改善游离脂肪酸诱导的 HepG2 细胞脂质蓄积与炎症反应,减少脂滴形成、阳性脂质及胞内甘油三酯含量,降低细胞上清液中 TNF-α、IL-6 水平,同时上调脂联素的蛋白与 mRNA 表达;该物质可激活 AMPKα 磷酸化并提升 AMPK mRNA 表达,在转录及蛋白层面下调 SREBP-1c、ACC、FAS,上调 CPT1、ACOX1,且对 PPARα 表达无明显影响。 Alisol A 24-acetate (compound 24A) (3-768 μM; 24 h) 以浓度依赖的方式降低 HK-2 细胞活力,其中 6 μM 处理后细胞活力为 96.20%,可用于后续实验。 Alisol A 24-acetate (6 μM; 24 h) 可下调 Bcl-2、Bcl-xl 的蛋白与 mRNA 表达以诱导 HK-2 细胞凋亡,上调 Kim-1、Clusterin、TFF-3 的蛋白及 mRNA 表达引发细胞肾毒性;同时通过升高 LC3II/LC3I 比值、上调 Beclin-1 与 LC3 的蛋白和 mRNA 水平,并抑制 PI3K/Akt/mTOR 通路,共同诱导 HK-2 细胞发生自噬。 Alisol A 24-acetate (6 μM; 48 h) 诱导的自噬可介导 HK-2 细胞的凋亡与肾毒性,因为与自噬抑制剂 3-MA 共孵育可逆转细胞活力丧失、降低 LC3II/LC3I 比值、上调抗凋亡蛋白 Bcl-2 并下调肾毒性生物标志物 Kim-1。 Alisol A 24-acetate (AA-24-a) (10-50 μM; 24-72 h) 可提高完全分化的 3T3-L1 脂肪细胞的存活率;可显著刺激完全分化的 3T3-L1 脂肪细胞的基础脂解作用。 Alisol A 24-acetate (50 μM; 12 h) 可改变完全分化的 3T3-L1 脂肪细胞中脂解相关基因的表达,上调 ATGL mRNA 水平,同时下调 HSL、PPARγ 和 perilipin A mRNA 水平。 Alisol A 24-acetate (30-50 μM; 20-36 h) 可增加完全分化的 3T3-L1 脂肪细胞中 ATGL 蛋白的表达和 HSL 在 Ser660 位点的磷酸化,同时激活 ERK 并降低 PPARγ 和 perilipin A 蛋白的水平。 Alisol A 24-acetate 在完全分化的 3T3-L1 脂肪细胞中诱导的脂解作用部分由 PKA 诱导的 HSL 在 Ser660 位点的磷酸化介导。 Alisol A 24-acetate (30-50 μM; 20 h) 可诱导完全分化的 3T3-L1 脂肪细胞发生脂解作用,该效应由 ERK 通路激活介导,通路活化进一步下调 PPARγ 和 perilipin A 表达;PD98059 (MS-N60869) 预处理可减少甘油释放并逆转上述分子改变。 Alisol A 24-acetate (24A) 可降低 HepG2 细胞中炎症因子 TNF−α、IL-1β、IL-6 和 IL-8 的水平;对氧糖剥夺损伤的脑微血管内皮细胞紧密连接起到保护作用;强效抑制 MRSA HMGR。 Alisol A 24-acetate (AA) 是 MRSA HMGR 的高亲和力配体,其 Kd 值为 30 μM。 Alisol A 24-acetate (20-40 μM; 24 h) 对 RAW 264.7 巨噬细胞和原代主动脉内皮细胞 HAEC 无细胞毒性。 Alisol A 24-acetate (10-40 μM) 以剂量依赖的方式提升金黄色葡萄球菌 ATCC 43300 的膜流动性。 Alisol A 24-acetate (20-50 μM) 可呈剂量依赖性地破坏金黄色葡萄球菌 ATCC 43300 的膜电位和膜完整性。 Alisol A 24-acetate (10-40 μM; 1-1.5 h) 可在 37 °C 孵育 1.5 h 后,以剂量依赖的方式提升金黄色葡萄球菌 ATCC 43300 的细胞内 ATP 水平和 ROS 水平。 Alisol A 24-acetate 对金黄色葡萄球菌 ATCC 43300 造成形态损伤 (不规则凹陷、表面塌陷)。 Alisol A 24-acetate (1-30 μM; 4 days) 可剂量依赖性地抑制 RANKL 和 M-CSF 诱导的小鼠骨髓来源巨噬细胞向破骨细胞分化。 Alisol A 24-acetate (10 μM; 30 min pre-incubation, 1-3 days RANKL stimulation) 可在 3 天刺激过程中显著抑制小鼠骨髓来源巨噬细胞中 RANKL 诱导的 NFATc1、TRAP、DC-STAMP 和组织蛋白酶 K 的 mRNA 表达。 Alisol A 24-acetate (预孵育 1 小时,RANKL 刺激 1-3 天) 可在 3 天刺激过程中显著抑制小鼠骨髓来源巨噬细胞中 RANKL 诱导的 NFATc1 蛋白表达
Cell Viability Assay
| Cell Line: |
HepG2 cells |
| Concentration: |
2.5 μM, 5 μM, 10 μM, 20 μM, 50 μM, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced HepG2 cell viability in a dose-dependent manner. Reduced viability at concentrations from 2.5 μM to 100 μM. Caused significant inhibition of cell proliferation at concentrations above 10 μM. Induced 23.85% cytotoxicity at 20 μM. |
ELISA Assay
| Cell Line: |
FFA-induced HepG2 cellular steatosis model |
| Concentration: |
10 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly reduced TNF-α, IL-6 levels in HepG2 cell supernatants.
|
RT-PCR
| Cell Line: |
FFA-induced HepG2 cellular steatosis model |
| Concentration: |
10 μM |
| Incubation Time: |
24 h |
| Result: |
Upregulated the expression of CPT1 and ACOX1; downregulated SREBP-1c, ACC, and FAS. |
Cell Viability Assay
| Cell Line: |
human renal proximal tubular (HK-2) cells |
| Concentration: |
3, 6, 12, 24, 48, 96, 192, 384, 768 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced HK-2 cell viability in a concentration-dependent manner. Yielded a cell viability of 96.20% at 6 μM for 24 h. |
Apoptosis Analysis
| Cell Line: |
human renal proximal tubular (HK-2) cells |
| Concentration: |
6 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly increased HK-2 cell apoptosis Significantly decreased protein expression of anti-apoptotic Bcl-2 and Bcl-xl. Significantly reduced mRNA levels of Bcl-2 and Bcl-xl. |
Cell Autophagy Assay
| Cell Line: |
human renal proximal tubular (HK-2) cells |
| Concentration: |
6 μM |
| Incubation Time: |
24 h |
| Result: |
Induced formation of numerous double-membrane autophagosomes and autophagic vacuoles containing degraded organelles. Significantly increased green fluorescence (LC3II accumulation). Significantly increased LC3II/LC3I ratio and Beclin-1 protein expression. Significantly elevated mRNA levels of LC3 and Beclin-1. |
Cell Viability Assay
| Cell Line: |
human renal proximal tubular (HK-2) cells |
| Concentration: |
6 μM; 6 μM plus 3-MA |
| Incubation Time: |
48 h |
| Result: |
Resulted in a cell viability of 50.71% when used alone for 48 h. Increased cell viability to 89.06% when co-incubated with 3-MA.
|
Cell Viability Assay
| Cell Line: |
fully differentiated 3T3-L1 adipocytes |
| Concentration: |
10, 20, 30, 40, 50 μM |
| Incubation Time: |
24 h; 48 h; 72 h |
| Result: |
Increased cell viability relative to untreated control cells by 10.3%, 12.0%, and 10.8% at 30, 40, and 50 μM for 24 h, respectively.
|
Real Time qPCR
| Cell Line: |
fully differentiated 3T3-L1 adipocytes |
| Concentration: |
50 μM |
| Incubation Time: |
12 h |
| Result: |
Significantly decreased mRNA expression of HSL, PPARγ, and perilipin A. Significantly increased ATGL mRNA expression. |
Western Blot Analysis
| Cell Line: |
fully differentiated 3T3-L1 adipocytes |
| Concentration: |
30, 50 μM (ATGL and HSL phosphorylation analysis); 30, 50 μM (ERK phosphorylation, PPARγ, and perilipin A analysis) |
| Incubation Time: |
36 h (ATGL and HSL phosphorylation analysis); 24 h (ERK phosphorylation, PPARγ, and perilipin A analysis) |
| Result: |
Elevated ATGL protein expression at 30 μM after 36 h treatment. Raised HSL phosphorylation at Ser660 by 54.2% relative to controls at 50 μM after 36 h treatment, while exerting no influence on HSL phosphorylation at Ser563 and Ser565. Increased ERK phosphorylation by 55.6% relative to controls at 50 μM after 24 h treatment. Downregulated PPARγ and perilipin A protein levels relative to controls at 50 μM after 24 h treatment. |
Cell Viability Assay
| Cell Line: |
RAW 264.7 macrophages, HAEC primary aortic endothelial cells |
| Concentration: |
20, 25, 30 μM (RAW 264.7); 30, 35, 40 μM (HAEC) |
| Incubation Time: |
24 h |
| Result: |
Showed no cytotoxicity to HAEC cells at 30, 35, or 40 μM, with cell viability remaining above 70%. Maintained RAW 264.7 cell viability near 100% at 20 and 25 μM, and above 75% at 30 μM. Confirmed no significant cell death in RAW 264.7 cells via Live/Dead staining at 20, 25, or 30 μM. |
...(内容过长已截断) |
体内研究 (In Vivo) |
Alisol A 24-acetate (compound 24A) (0.5 g/kg;口服;每日;持续 6 个月) 可诱导雌性 Sprague Dawley 大鼠产生肾毒性,肾脏的病理变化以及 Kim-1、Clusterin 和 TFF-3 的蛋白水平显著升高可证明这一点。 Alisol A 24-acetate (24A) (30 mg/kg;口服;每日 1 次;连续 7 天) 可通过激活 PI3K/AKT 通路,抑制神经炎症与细胞凋亡、改善神经及认知功能并恢复脑代谢,从而缓解雄性 C57BL/6J 小鼠的全脑缺血再灌注损伤。 Alisol A 24-acetate (AA) (20-30 μM;左侧后腹足注射;单次给药) 可提高 MRSA 感染的 Galleria mellonella 幼虫的存活率。 Alisol A 24-acetate (100 μM;涂抹给药;每日 1 次;连续 8 天) 可降低小鼠 MRSA 皮肤伤口感染模型中的 MRSA 载菌量、促进伤口愈合并下调 IL-1β 的表达。
| Animal Model: |
C57BL/6J (male, 12 weeks old, 25-30 g, global cerebral ischaemia-reperfusion injury induced by two-vessel occlusion) |
| Dosage: |
30 mg/kg |
| Administration: |
p.o.; once daily; 7 consecutive days (initiated 24 hours after reperfusion) |
| Result: |
Ameliorated neurological deficit scores at days 1, 3, 5 and 7. Improved learning and memory abilities, with shorter escape latency and travel distance, and longer residence time in the target quadrant. Enhanced novel object recognition by raising discrimination index and time ratio. Regulated brain metabolite levels by lowering Glx/Cr, MI/Cr, CHO/Cr and Taurine/Cr, and elevating GABA/Cr and NAA/Cr. Suppressed activation of microglia and astrocytes in hippocampus and cortex. Alleviated neuroinflammation and apoptosis, and decreased levels of IL-1β, TNF-α, iNOS, Bax/Bcl-2 and cleaved Caspase-3. Protected neuronal morphology, increased neuronal quantity and dendritic spine density. Activated PI3K/AKT pathway and elevated p-PI3K/PI3K and p-AKT/AKT ratios. |
| Animal Model: |
ICR (female, 6 weeks old) |
| Dosage: |
100 μM |
| Administration: |
smear route; once daily; 8 days |
| Result: |
Reduced bacterial load in infected skin tissue. Promoted wound healing with significant reduction in wound size over 8 days. Increased epidermal thickness and collagen deposition in infected skin. Decreased relative expression of the inflammatory cytokine IL-1β in infected tissue compared to the infected control group. |
|